PMC

(A) For Parkinson disease (PD) patients versus controls, the combination of DJ-1 and Flt3 ligand (solid) and the combination of phosphorylated tau (p-tau), total tau (t-tau) and amyloid beta peptide 1-42 (Aβ_1-42) (dot-dash) were the best discriminating parameters along with DJ-1 (dot) and α-synuclein (not shown) alone (see also ). (B) For PD versus multiple system atrophy (MSA), Flt3 ligand (solid) and the combination of α-synuclein and p-tau% (p-tau/t-tau) (dot) were the best discriminating parameters. (C) For MSA patients versus controls, Flt3 ligand (solid) along with the combination of DJ-1 and p-tau% (dot) were the best discriminating parameters.

(A) CSF fractalkine and Aβ_1-42 levels in cross-sectional CSF samples were measured by Luminex and the fractalkine/Aβ_1-42 ratio correlated with disease severity as measured by UPDRS motor scores (r=0.252, P<0.01) using linear regression analysis with Pearson’s correlation. (B) A similar trend was observed between the fractalkine/Aβ_1-42 ratio and Hoehn and Yahr (H&Y) stages in a small independent PD cohort (UPDRS not available); however, the correlation was not statistically significant (r=0.216, P>0.05). (C) In an independent longitudinally collected sample set, the fold change of fractalkine/Aβ_1-42 (endpoint/baseline) was also well correlated with the annual rate of UPDRS (motor) progression (r=0.325, P<0.05, Pearson’s correlation).